UI Hospitals and Clinics
A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND# 58,443) in Combination with Intensive Re-Induction Therapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Participants in this study have been diagnosed with acute lymphoblastic leukemia (ALL) or a cancer of the immune system tissue. The purpose of this study is test effectiveness of adding a drug called bortezomib to the standard therapy for relapsed ALL. Approximately 6 people will take part in this study conducted by investigators at the University of Iowa. Study involvement will last approximately 15 weeks.
Victoria Scaccia, 319-356-7875
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.